NASDAQ:REPL Replimune Group Q1 2027 Earnings Results & Report $11.75 +0.36 (+3.16%) Closing price 04:00 PM EasternExtended Trading$11.80 +0.05 (+0.43%) As of 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Replimune Group missed analyst earnings expectations in its Q1 2027 results, released August 14, 2026. The company reported EPS of -$0.72 versus the -$0.6940 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateAugust 14, 2026TimeBefore Market OpensConference Call7:00 AM ET Replimune Group EPS ResultsActual EPS-$0.72Consensus EPS -$0.6940Beat/MissMissed by -$0.0260One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersReplimune Group Revenue ResultsActual RevenueN/AExpected Revenue$13.60 millionBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsReplimune Group's Q2 2027 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Replimune Group Q1 2027 Earnings FAQ Did Replimune Group beat earnings estimates for Q1 2027? Replimune Group (NASDAQ:REPL) reported earnings of -$0.72 per share for Q1 2027, missing the consensus estimate of -$0.6940. The report was announced on Friday, August 14, 2026. When is Replimune Group's next earnings date? Replimune Group's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Replimune Group on the company's earnings history page. Replimune Group Earnings HeadlinesReplimune Group, Inc. (NASDAQ:REPL) Stock Has Consensus Target Price of $12.00October 13 at 4:15 AM | americanbankingnews.comReplimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into FocusOctober 9, 2026 | finance.yahoo.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor HarmOctober 5, 2026 | globenewswire.comReplimune Group, Inc. Announces Tudriqev? Now Commercially Available in the United States for Advanced MelanomaOctober 2, 2026 | marketscreener.comMREPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5thOctober 2, 2026 | globenewswire.comSee More Replimune Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email. Email Address About Replimune GroupReplimune Group (NASDAQ:REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for the treatment of cancer. The company’s approach uses genetically engineered viruses designed to selectively replicate in tumors, directly destroy cancer cells and stimulate a broader immune response against malignant tissue. Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 intended for use in patients with advanced solid tumors. The company has evaluated RP1 as a standalone therapy and in combination with immune checkpoint inhibitors. Its pipeline has also included additional investigational oncolytic immunotherapies, including RP2 and RP3, which are designed with different payloads and mechanisms to enhance antitumor immune activity. Founded in 2015, Replimune is headquartered in the United States and conducts clinical development through research and collaborations involving patients with advanced cancers in multiple regions. The company’s programs remain focused on advancing novel immunotherapies through clinical testing and potential regulatory approval.View Replimune Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
